We Don't Sell Treatment.
We Engineer Access.
CancerCareE is not a hospital, not a medical provider, and not a tourism company. We are an intelligence platform that engineers intelligent pathways connecting patients to advanced cancer therapies at 200+ partner institutions across 8 countries — including public hospitals, private centers, and clinical trial sites.
- $0 patient fees — always. We never charge patients.
- Free second opinion from board-certified oncologists within 48 hours
- Access to 700+ CAR-T clinical trials in China alone
- 200+ partner institutions: public hospitals, private centers, trial sites
- Dedicated Physician Referral Portal for licensed oncologists
Start Your Free Case Review
Submit your medical records for a no-obligation assessment. Our oncology team will respond within 48 hours with a clear roadmap of your options.
Real-Time Platform Transparency
Data from our coordination network. Updated regularly. No marketing claims — just facts.
Who We Serve
Whether you're a patient, a family member, or a referring physician — we have a pathway for you.
For Patients & Families
- Free initial case review within 48 hours
- Access to therapies unavailable locally
- Transparent cost information
- Multi-language coordination support
For Advanced Cancer Cases
- Relapsed or refractory blood cancers
- Solid tumors exhausting standard options
- Candidates for CAR-T, TIL, NK, Gamma Delta
- Clinical trial matching across continents
For Referring Physicians
- Secure physician-to-physician portal
- Peer case review by specialist oncologists
- Clinical trial matching API
- Outcome data sharing (anonymized)
Global Access Pathways
200+ partner institutions across 8 countries — public hospitals, private centers, and clinical trial sites.
China
World leader in CAR-T research. 700+ active trials. Public & private hospitals.
PRIMARY NETWORKSouth Korea
Advanced immunotherapy centers. Samsung, Asan, Seoul National University.
Singapore
Premium oncology hub. National Cancer Centre, Mount Elizabeth, Parkway.
India
Cost-effective advanced care. Tata, Apollo, AIIMS, Rajiv Gandhi Cancer.
Turkey
JCI-accredited hospitals. Arabic & English support. Strategic location.
Germany
European oncology excellence. Charité, Heidelberg, LMU Munich.
USA
FDA-approved therapies. MD Anderson, Memorial Sloan Kettering, Mayo Clinic.
Therapy Intelligence
Evidence-based information on advanced cellular and immunotherapy treatments.
CAR-T Cell Therapy
Genetically modified T-cells targeting specific cancer antigens (CD19, BCMA, CD22). Breakthrough for blood cancers.
Source: ClinicalTrials.gov ↗
Gamma Delta T-Cell Therapy
Innate immune cells effective against solid tumors without requiring HLA matching. Off-the-shelf availability.
Source: PubMed ↗
TIL Therapy
Tumor-Infiltrating Lymphocytes expanded from the patient's own tumor to fight metastatic disease.
Source: PubMed ↗
NK Cell Therapy
Natural Killer cells providing innate immunity against cancer cells, with lower risk of cytokine release syndrome.
Source: PubMed ↗
Is Advanced Cellular Therapy Right for You?
An honest assessment framework. We tell you when it's appropriate — and when it's not.
Strong Candidate If
- Relapsed after 2+ standard treatments
- Specific cancer type (B-ALL, DLBCL, Myeloma)
- Adequate organ function (liver, kidney, heart)
- No active uncontrolled infection
- Performance status ECOG 0-2
Not Suitable If
- Early-stage cancer (standard treatment works)
- Severe organ dysfunction
- Active autoimmune disease (relative)
- Performance status ECOG 3-4
- Untreated active infection
Requires Expert Review If
- Solid tumors (trial-dependent)
- Elderly patients (case-by-case)
- Prior CAR-T failure
- Rare cancer types
- Complex medical history
This is an informational guide, not medical advice. Final eligibility is determined by licensed physicians.
The Truth About CAR-T in China
No marketing claims. No hidden realities. Just facts — the good, the challenging, and what we won't promise.
What's Real & Verified
- 700+ active CAR-T clinical trials (ClinicalTrials.gov verified)
- $30K-$80K cost range (documented from partner hospitals)
- JCI-accredited partner hospitals in major cities
- Published remission data from peer-reviewed studies
- Legal right for international patients to seek treatment
What's Challenging
- Language barriers (we provide translation support)
- Regulatory differences vs. your home country
- Follow-up care logistics after returning home
- Not all trials accept international patients
- Travel and accommodation costs are additional
What We Won't Promise
- Guaranteed treatment outcomes or cures
- Same-day approvals or instant access
- Treatment for every case (we say no when appropriate)
- Replacement for your local physician's care
- Hidden fees disguised as "coordination costs"
Compare Treatment Options
Evidence-based comparisons to help you make informed decisions.
CAR-T vs Chemotherapy
Compare efficacy, side effects, and costs between cellular therapy and traditional chemotherapy.
Read comparisonTIL vs Immunotherapy
Are tumor-infiltrating lymphocytes more effective than immune checkpoint inhibitors?
Read comparisonNK Cells vs CAR-T
Natural killer cells or modified T-cells: which is right for your case?
Read comparisonChina vs USA in Cellular Therapy
Comprehensive comparison: cost, wait times, clinical trials, and quality of care.
Read comparisonData & Insights
Facts and figures based on the latest studies and our network data.
CAR-T Cost by Country
China: $30-80K | USA: $375-500K | India: $40-90K
Treatment Wait Time
China: 2-4 weeks | USA & Europe: 4-8 weeks
Active Clinical Trials
China leads the world in CAR-T and immunotherapy trials
Survival Improvement
Improved survival with cellular therapy vs chemotherapy in eligible patients
Your Patient Journey
A clear, transparent 5-step process from initial inquiry to treatment completion.
Medical Records Review
Submit your pathology reports, imaging, and treatment history. Our oncology team conducts a thorough initial assessment within 48 hours.
Center Matching
We match your case with partner oncology centers based on your specific cancer type, stage, and treatment goals.
Treatment Proposal
Receive detailed treatment plans with transparent pricing, expected outcomes, and timeline from one or more centers.
Admission & Ethics Approval
Official admission from the partner hospital. For clinical trials, ethics committee approval is obtained.
Treatment & Ongoing Support
We coordinate travel, medical visa assistance, accommodation, translation, and provide non-medical support throughout your journey.
Why Choose CancerCareE
Our approach based on trust, transparency, and science.
Fully Transparent Process
Clear communication at every step. No hidden fees. No surprises. Ever.
Global Oncology Network
200+ partner institutions across 8 countries including China, India, S. Korea, Turkey, USA, Germany, and Singapore.
Dedicated Coordination Team
Personal coordinator assisting with all non-medical aspects of your journey.
Multi-Language Support
Coordination available in English, Arabic, Turkish, Russian, Persian, Chinese, and Korean.
Cellular Therapy Specialization
We focus exclusively on advanced cancer therapies — CAR-T, TIL, NK, Gamma Delta.
Clear & Transparent Role
We are access coordinators, not a hospital. We never replace your physician's judgment.
For Referring Physicians
A dedicated portal for licensed oncologists who want to expand treatment options for their patients.
Physician Referral Portal
Secure, HIPAA-aligned platform for referring patients to our network. Direct physician-to-physician communication.
Access PortalPeer Case Review
Request peer review of complex cases by specialist oncologists in our partner network.
Request ReviewClinical Trial Matching
Access our database of 700+ active trials. Match your patients to appropriate studies in real-time.
Search TrialsOutcome Data Sharing
Access anonymized outcome data from our network to inform your clinical decisions.
View DataAvailable to licensed oncologists and hematologists only.
Our Partner Oncologists
Meet the specialists leading cellular therapy at our partner centers.
Dr. Brian Liu, MD, PhD
Pioneer in CAR-T cell therapy for hematologic malignancies and cutting-edge gene therapy approaches in China.
View Full Profile
Dr. Qian Li, MD
Expert in CAR-T therapy for refractory blood disorders and stem cell transplantation in China.
View Full Profile
Dr. Yafei Wang, MD
Leading specialist in multiple myeloma, lymphoma, leukemia, and advanced transplant techniques.
View Full ProfilePatient Success Stories
Real journeys of international patients who accessed advanced cancer treatments through our coordination.
After relapsing with 90% blast cells, CAR-T therapy in China achieved complete remission when all other options had failed.
Traveled from Russia for neuroblastoma treatment — comprehensive coordination made the journey seamless and successful.
Targeted CAR-T therapy in China offered new hope when conventional treatments failed. Saved over £300,000 vs UK private care.
Medical Library
Trusted educational content about advanced cancer treatments.
What After Traditional Treatment Failure?
Understanding treatment pathways for patients who have exhausted conventional options.
Read Article
CAR-T and Cellular Therapy Basics
Comprehensive patient guide to cellular immunotherapies.
Read Article
Treatment Access Guides: Asia and Europe
Practical information for international patients.
Read ArticleFrequently Asked Questions
Common questions about our platform and services.
CancerCareE is an international oncology access intelligence platform, not a healthcare provider, hospital, or medical practice. We engineer intelligent pathways connecting patients to advanced cancer therapies at 200+ partner institutions across 8 countries.
Patient coordination services are provided at absolutely no cost to patients. Our platform is sustained through institutional partnerships with hospitals and research centers. Patients never pay us any fees or commissions.
No. We are an oncology access intelligence platform. We do not sell treatment packages, charge patients, or act as medical tourism agents. We coordinate access to care through our partner hospital network.
No ethical organization can guarantee medical outcomes. We provide transparent data, evidence-based information, and access to qualified physicians. All medical decisions are made by licensed physicians at partner institutions.
We coordinate access through a network of 200+ partner institutions across 8 countries including China, India, South Korea, Turkey, USA, Germany, and Singapore, including public hospitals, private centers, and clinical trial sites.
Yes. We have a dedicated Physician Referral Portal for licensed oncologists who wish to refer patients for peer review, clinical trial matching, or access to advanced therapies not available locally.
For Hospitals, Physicians & Medical Partners
Are you an oncology center or medical professional interested in joining our international patient network?
Explore Partnership Opportunities